Abstract Objective To observe the clinical therapeutic effect of OM-85 BV(OM-85 Broncho-Vaxom) in children with asthma and recurrent respiratory tract infection, and the effect of OM-85 BV on human β-defensins 1 (hBD-1) and immunoglobulin levels. Methods Sixty-two children with asthma and recurrent respiratory infection treated between 2011 January and December were divided into two groups by the randomized, double blind method: a treatment group and a control group. With inhaling corticosteroids, the treatment group was given OM-85 BV, and the control group was given a placebo. Clinical curative effects and adverse reactions were observed. Serum levels of hBD-1, IgA, IgG, IgM and urea and alanine aminotransferase (ALT) were measured before treatment and 6 months and 12 months after treatment. Results Compared with the control group and before treatment, the frequency of respiratory tract infection was reduced in the treatment group 6 months and 12 months after treatment (PPP>0.05). Mild adverse reactions occurred in 3 cases in the two groups, 2 cases of abdominal pain and 1 cases of constipation. Conclusions OM-85 BV can improve serum levels of hBD-1, IgA and IgG, reduce the occurrence of acute respiratory tract infection and cause mild adverse reactions, suggesting its satisfactory therapeutic effect and safety in the treatment of asthma combined with recurrent respiratory tract infection in children.
LIAO Jia-Yi,ZHANG Tao. Influence of OM-85 BV on hBD-1 and immunoglobulin in children with asthma and recurrent respiratory tract infection[J]. CJCP, 2014, 16(5): 508-512.
LIAO Jia-Yi,ZHANG Tao. Influence of OM-85 BV on hBD-1 and immunoglobulin in children with asthma and recurrent respiratory tract infection[J]. CJCP, 2014, 16(5): 508-512.
Gutierrez-Tarango MD, Berber A. Safety and efficacy of two courses of OM-85 BV in the prevention of respiratory tract infections in children during 12 months[J]. CHEST, 2001, 119(6): 1742-1748.
[11]
Bacharier LB, Boner A, Carlsen KH, et al. Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report[J]. Allergy, 2008, 63(1): 5-34.
[12]
Papadopoulos NG, Arakawa H, Carlsen KH, et al. International consensus on (ICON) pediatric asthma[J]. Allergy, 2012, 67(8): 976-997.
[13]
The GINA Board of Directors, The GINA Science Committee. Global strategy for asthma management and prevention 2012(update)[EB/OL]. [2013-11-19].
[14]
De Moraes Lui C, Oliveira LC, Diogo CL, et al. Immunoglobulin G subclass concentrations and infections in children and adolescents with severe asthma[J]. Pediatr Allergy Immunol, 2002, 13(3): 195-202.
[15]
Pfefferle PI, Prescott SL, Kopp M. Microbial influence on tolerance and opportunities for intervention with prebiotics/probiotics and bacterial lysates[J]. J Allergy Clin Immunol, 2013, 131(6): 1453-1463.
[16]
Schaad UB. OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review[J]. World J Pediatr, 2010, 6(1): 5-12.
[17]
Matsushita I, Hasegawa K, Nakata K, et al. Genetic variants of human beta-defensin-1 and chronic obstructive pulmonary disease[J]. Biochem Biophys Res Commun, 2002, 291(1): 17-22.
